References
1. Lobe C, Hankins JS, Moura P, Pinto JC. Hydroxyurea therapy reduces mortality among children with sickle cell disease.Blood.2010;116:843-5.
2.Thomas R, Dulman R, Lewis A, Notarangelo B, Yang E. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy. Pediatr Blood Cancer.2019; 66: 27816.
3. Galadanci N, Wudil BJ, Balogun TM, Ogunrinde GO, Akinsulie A, Hasan-hanga F et al. Current sickle cell disease management practices in Nigeria.  Int Health. 2014; 6:23-8.
4. Ojewumi OO, Adeyemo TA, Ayinde OC, Iwalokun B, Adekile A. Current perspectives of sickle cell disease in Nigeria: changing narratives. Expert Rev Hematol. 2020;12:609-20.
5. Dubert M, Elion J, Tolo A, Diallo DA, Diop S, Diagne I et al. Degree of anemia, indirect markers of hemodialysis, and vascular complications of sickle cell disease in Africa. Blood.2017; 130: 2215-23.
6. Green NS, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res. 2014; 75:196-204.
7. Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE et al. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Med(Baltimore) 2014; 93:215.
8.Akinsete AM. Experience with hydroxycarbamide use, indications, adverse effects and clinical course at a tertiary hospital in Lagos. Big Qtrly J Hosp Med. 2018; 28: 26-30.
9. Ofokunrin AOD, Adekoba KU, Oguche S, Okpe ES, Sagay AS. Efficacy and safety of hydroxyurea in the treatment of sickle cell  disease in children in Jos, North central Nigeria. Blood. 2018;132:1081.
10. Pooja RO, Ndugwu CM, Latham TS, Lane A, Hume HA, Kasirye P et al. Novel use of hydroxyurea in an African region with malaria(NOHARM): a randomized controlled trial. Blood. 2017; 130: 2585- 93.
11. Tshilolo L, Tomlinson G, William’s TN, Santos B, Olupot- Olupot P, Lanre A, at al. Hydroxyurea for children with sickle cell anemia in sub- Sahara Africa (REACH). N Engl J Med. 2019;380: 121-31.
12. Luzzatto L, Makani J. Hydroxyurea- An essential medicine for sickle cell disease in Africa.N Engl J Med. 2019; 380: 187-9
13. Russell E, Ware MD. Hydroxycarbamide: clinical aspects. C R Biol. 2013; 336: 177-82.
14. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med.
2008; 358: 1362-9.
15. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP et al. pharmacokinetics, pharmacodynamics, and pharmacokinetics of hydroxyurea treatment for children with sickle cell anemia.  Blood. 2011; 118:4985-91.
16. Gwilt PR. Pharmacokinetics and pharmacodynamics of hydroxyurea.  Clin Pharmacokinet. 1998;34:347-58.
17. Yan JH, Ataga K, Kaul S, Olson JS, Grasela DM, Gothelf S, Kutlar A, Orringer E. The influence  of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol. 2005;45:434-45.
18. Scott TM, Kathy R, Jin H, Jonathan F, Billie JF, Zora RR, Winfred CN. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.  Pediatr Blood Cancer. 2012; 59: 170-2.
19. Wang WC, Wynn LW, Roger’s ZR, Scott JP, Lane PA, Ware RE. A two- year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr.  2001; 139: 790- 6.
20. American Academy of Pediatrics Committee on injury,  violence and poison treatment in the home. Pediatr. 2003; 112:1182-5.